Elevation of inositol pyrophosphate IP 7 in the mammalian spinal cord of amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder associated with progressive impairment of spinal motor neurons. Continuous research endeavor is underway to fully understand the molecular mechanisms associating with this disorder. Although several studies have implied the in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in neurology 2023, Vol.14, p.1334004
Hauptverfasser: Ito, Masatoshi, Fujii, Natsuko, Kohara, Saori, Tanaka, Masayuki, Takao, Masaki, Mihara, Ban, Saito, Yuko, Mizuma, Atsushi, Nakayama, Taira, Netsu, Shizuka, Suzuki, Naoto, Kakita, Akiyoshi, Nagata, Eiichiro
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 1334004
container_title Frontiers in neurology
container_volume 14
creator Ito, Masatoshi
Fujii, Natsuko
Kohara, Saori
Tanaka, Masayuki
Takao, Masaki
Mihara, Ban
Saito, Yuko
Mizuma, Atsushi
Nakayama, Taira
Netsu, Shizuka
Suzuki, Naoto
Kakita, Akiyoshi
Nagata, Eiichiro
description Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder associated with progressive impairment of spinal motor neurons. Continuous research endeavor is underway to fully understand the molecular mechanisms associating with this disorder. Although several studies have implied the involvement of inositol pyrophosphate IP in ALS, there is no direct experimental evidence proving this notion. In this study, we analyzed inositol pyrophosphate IP and its precursor IP in the mouse and human ALS biological samples to directly assess whether IP level and/or its metabolism are altered in ALS disease state. We used a liquid chromatography-mass spectrometry (LC-MS) protocol originally-designed for mammalian IP and IP analysis. We measured the abundance of these molecules in the central nervous system (CNS) of ALS mouse model (G93A) transgenic (TG) mice as well as postmortem spinal cord of ALS patients. Cerebrospinal fluid (CSF) and peripheral blood mononuclear cells (PBMCs) from ALS patients were also analyzed to assess if IP status in these biofluids is associated with ALS disease state. (G93A) TG mice showed significant increase of IP level in the spinal cord compared with control mice at the late stage of disease progression, while its level in cerebrum and cerebellum remains constant. We also observed significantly elevated IP level and its product-to-precursor ratio (IP /IP ) in the postmortem spinal cord of ALS patients, suggesting enhanced enzymatic activity of IP -synthesizing kinases in the human ALS spinal cord. In contrast, human CSF did not contain detectable level of IP and IP , and neither the IP level nor the IP /IP ratio in human PBMCs differentiated ALS patients from age-matched healthy individuals. By directly analyzing IP in the CNS of ALS mice and humans, the findings of this study provide direct evidence that IP level and/or the enzymatic activity of IP -generating kinases IP6Ks are elevated in ALS spinal cord. On the other hand, this study also showed that IP is not suitable for biofluid-based ALS diagnosis. Further investigation is required to elucidate a role of IP in ALS pathology and utilize IP metabolism on the diagnostic application of ALS.
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_38274887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>38274887</sourcerecordid><originalsourceid>FETCH-pubmed_primary_382748873</originalsourceid><addsrcrecordid>eNqFjssKwjAQRYMotmh_QeYHBG1qH2up6M6F-zK2KY3kRRKF_r0pKLhzNjNw7hnujMT7PM-2aVod5j93RBLnHrswtKpoTpckomVaZGVZxKSvBXuh51qB7oEr7bjXAsxotRm0MwN6BpcrFIGBHxhIlBIFRwXOcIUCWm27yUU5aj9ZvAURLBuYawWz4aVbk0WPwrHks1dkc6pvx_PWPO-SdY2xXKIdm28x-jfwBk0hR44</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Elevation of inositol pyrophosphate IP 7 in the mammalian spinal cord of amyotrophic lateral sclerosis</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Ito, Masatoshi ; Fujii, Natsuko ; Kohara, Saori ; Tanaka, Masayuki ; Takao, Masaki ; Mihara, Ban ; Saito, Yuko ; Mizuma, Atsushi ; Nakayama, Taira ; Netsu, Shizuka ; Suzuki, Naoto ; Kakita, Akiyoshi ; Nagata, Eiichiro</creator><creatorcontrib>Ito, Masatoshi ; Fujii, Natsuko ; Kohara, Saori ; Tanaka, Masayuki ; Takao, Masaki ; Mihara, Ban ; Saito, Yuko ; Mizuma, Atsushi ; Nakayama, Taira ; Netsu, Shizuka ; Suzuki, Naoto ; Kakita, Akiyoshi ; Nagata, Eiichiro</creatorcontrib><description>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder associated with progressive impairment of spinal motor neurons. Continuous research endeavor is underway to fully understand the molecular mechanisms associating with this disorder. Although several studies have implied the involvement of inositol pyrophosphate IP in ALS, there is no direct experimental evidence proving this notion. In this study, we analyzed inositol pyrophosphate IP and its precursor IP in the mouse and human ALS biological samples to directly assess whether IP level and/or its metabolism are altered in ALS disease state. We used a liquid chromatography-mass spectrometry (LC-MS) protocol originally-designed for mammalian IP and IP analysis. We measured the abundance of these molecules in the central nervous system (CNS) of ALS mouse model (G93A) transgenic (TG) mice as well as postmortem spinal cord of ALS patients. Cerebrospinal fluid (CSF) and peripheral blood mononuclear cells (PBMCs) from ALS patients were also analyzed to assess if IP status in these biofluids is associated with ALS disease state. (G93A) TG mice showed significant increase of IP level in the spinal cord compared with control mice at the late stage of disease progression, while its level in cerebrum and cerebellum remains constant. We also observed significantly elevated IP level and its product-to-precursor ratio (IP /IP ) in the postmortem spinal cord of ALS patients, suggesting enhanced enzymatic activity of IP -synthesizing kinases in the human ALS spinal cord. In contrast, human CSF did not contain detectable level of IP and IP , and neither the IP level nor the IP /IP ratio in human PBMCs differentiated ALS patients from age-matched healthy individuals. By directly analyzing IP in the CNS of ALS mice and humans, the findings of this study provide direct evidence that IP level and/or the enzymatic activity of IP -generating kinases IP6Ks are elevated in ALS spinal cord. On the other hand, this study also showed that IP is not suitable for biofluid-based ALS diagnosis. Further investigation is required to elucidate a role of IP in ALS pathology and utilize IP metabolism on the diagnostic application of ALS.</description><identifier>ISSN: 1664-2295</identifier><identifier>EISSN: 1664-2295</identifier><identifier>PMID: 38274887</identifier><language>eng</language><publisher>Switzerland</publisher><ispartof>Frontiers in neurology, 2023, Vol.14, p.1334004</ispartof><rights>Copyright © 2024 Ito, Fujii, Kohara, Tanaka, Takao, Mihara, Saito, Mizuma, Nakayama, Netsu, Suzuki, Kakita and Nagata.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38274887$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ito, Masatoshi</creatorcontrib><creatorcontrib>Fujii, Natsuko</creatorcontrib><creatorcontrib>Kohara, Saori</creatorcontrib><creatorcontrib>Tanaka, Masayuki</creatorcontrib><creatorcontrib>Takao, Masaki</creatorcontrib><creatorcontrib>Mihara, Ban</creatorcontrib><creatorcontrib>Saito, Yuko</creatorcontrib><creatorcontrib>Mizuma, Atsushi</creatorcontrib><creatorcontrib>Nakayama, Taira</creatorcontrib><creatorcontrib>Netsu, Shizuka</creatorcontrib><creatorcontrib>Suzuki, Naoto</creatorcontrib><creatorcontrib>Kakita, Akiyoshi</creatorcontrib><creatorcontrib>Nagata, Eiichiro</creatorcontrib><title>Elevation of inositol pyrophosphate IP 7 in the mammalian spinal cord of amyotrophic lateral sclerosis</title><title>Frontiers in neurology</title><addtitle>Front Neurol</addtitle><description>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder associated with progressive impairment of spinal motor neurons. Continuous research endeavor is underway to fully understand the molecular mechanisms associating with this disorder. Although several studies have implied the involvement of inositol pyrophosphate IP in ALS, there is no direct experimental evidence proving this notion. In this study, we analyzed inositol pyrophosphate IP and its precursor IP in the mouse and human ALS biological samples to directly assess whether IP level and/or its metabolism are altered in ALS disease state. We used a liquid chromatography-mass spectrometry (LC-MS) protocol originally-designed for mammalian IP and IP analysis. We measured the abundance of these molecules in the central nervous system (CNS) of ALS mouse model (G93A) transgenic (TG) mice as well as postmortem spinal cord of ALS patients. Cerebrospinal fluid (CSF) and peripheral blood mononuclear cells (PBMCs) from ALS patients were also analyzed to assess if IP status in these biofluids is associated with ALS disease state. (G93A) TG mice showed significant increase of IP level in the spinal cord compared with control mice at the late stage of disease progression, while its level in cerebrum and cerebellum remains constant. We also observed significantly elevated IP level and its product-to-precursor ratio (IP /IP ) in the postmortem spinal cord of ALS patients, suggesting enhanced enzymatic activity of IP -synthesizing kinases in the human ALS spinal cord. In contrast, human CSF did not contain detectable level of IP and IP , and neither the IP level nor the IP /IP ratio in human PBMCs differentiated ALS patients from age-matched healthy individuals. By directly analyzing IP in the CNS of ALS mice and humans, the findings of this study provide direct evidence that IP level and/or the enzymatic activity of IP -generating kinases IP6Ks are elevated in ALS spinal cord. On the other hand, this study also showed that IP is not suitable for biofluid-based ALS diagnosis. Further investigation is required to elucidate a role of IP in ALS pathology and utilize IP metabolism on the diagnostic application of ALS.</description><issn>1664-2295</issn><issn>1664-2295</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFjssKwjAQRYMotmh_QeYHBG1qH2up6M6F-zK2KY3kRRKF_r0pKLhzNjNw7hnujMT7PM-2aVod5j93RBLnHrswtKpoTpckomVaZGVZxKSvBXuh51qB7oEr7bjXAsxotRm0MwN6BpcrFIGBHxhIlBIFRwXOcIUCWm27yUU5aj9ZvAURLBuYawWz4aVbk0WPwrHks1dkc6pvx_PWPO-SdY2xXKIdm28x-jfwBk0hR44</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Ito, Masatoshi</creator><creator>Fujii, Natsuko</creator><creator>Kohara, Saori</creator><creator>Tanaka, Masayuki</creator><creator>Takao, Masaki</creator><creator>Mihara, Ban</creator><creator>Saito, Yuko</creator><creator>Mizuma, Atsushi</creator><creator>Nakayama, Taira</creator><creator>Netsu, Shizuka</creator><creator>Suzuki, Naoto</creator><creator>Kakita, Akiyoshi</creator><creator>Nagata, Eiichiro</creator><scope>NPM</scope></search><sort><creationdate>2023</creationdate><title>Elevation of inositol pyrophosphate IP 7 in the mammalian spinal cord of amyotrophic lateral sclerosis</title><author>Ito, Masatoshi ; Fujii, Natsuko ; Kohara, Saori ; Tanaka, Masayuki ; Takao, Masaki ; Mihara, Ban ; Saito, Yuko ; Mizuma, Atsushi ; Nakayama, Taira ; Netsu, Shizuka ; Suzuki, Naoto ; Kakita, Akiyoshi ; Nagata, Eiichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_382748873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ito, Masatoshi</creatorcontrib><creatorcontrib>Fujii, Natsuko</creatorcontrib><creatorcontrib>Kohara, Saori</creatorcontrib><creatorcontrib>Tanaka, Masayuki</creatorcontrib><creatorcontrib>Takao, Masaki</creatorcontrib><creatorcontrib>Mihara, Ban</creatorcontrib><creatorcontrib>Saito, Yuko</creatorcontrib><creatorcontrib>Mizuma, Atsushi</creatorcontrib><creatorcontrib>Nakayama, Taira</creatorcontrib><creatorcontrib>Netsu, Shizuka</creatorcontrib><creatorcontrib>Suzuki, Naoto</creatorcontrib><creatorcontrib>Kakita, Akiyoshi</creatorcontrib><creatorcontrib>Nagata, Eiichiro</creatorcontrib><collection>PubMed</collection><jtitle>Frontiers in neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ito, Masatoshi</au><au>Fujii, Natsuko</au><au>Kohara, Saori</au><au>Tanaka, Masayuki</au><au>Takao, Masaki</au><au>Mihara, Ban</au><au>Saito, Yuko</au><au>Mizuma, Atsushi</au><au>Nakayama, Taira</au><au>Netsu, Shizuka</au><au>Suzuki, Naoto</au><au>Kakita, Akiyoshi</au><au>Nagata, Eiichiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevation of inositol pyrophosphate IP 7 in the mammalian spinal cord of amyotrophic lateral sclerosis</atitle><jtitle>Frontiers in neurology</jtitle><addtitle>Front Neurol</addtitle><date>2023</date><risdate>2023</risdate><volume>14</volume><spage>1334004</spage><pages>1334004-</pages><issn>1664-2295</issn><eissn>1664-2295</eissn><abstract>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder associated with progressive impairment of spinal motor neurons. Continuous research endeavor is underway to fully understand the molecular mechanisms associating with this disorder. Although several studies have implied the involvement of inositol pyrophosphate IP in ALS, there is no direct experimental evidence proving this notion. In this study, we analyzed inositol pyrophosphate IP and its precursor IP in the mouse and human ALS biological samples to directly assess whether IP level and/or its metabolism are altered in ALS disease state. We used a liquid chromatography-mass spectrometry (LC-MS) protocol originally-designed for mammalian IP and IP analysis. We measured the abundance of these molecules in the central nervous system (CNS) of ALS mouse model (G93A) transgenic (TG) mice as well as postmortem spinal cord of ALS patients. Cerebrospinal fluid (CSF) and peripheral blood mononuclear cells (PBMCs) from ALS patients were also analyzed to assess if IP status in these biofluids is associated with ALS disease state. (G93A) TG mice showed significant increase of IP level in the spinal cord compared with control mice at the late stage of disease progression, while its level in cerebrum and cerebellum remains constant. We also observed significantly elevated IP level and its product-to-precursor ratio (IP /IP ) in the postmortem spinal cord of ALS patients, suggesting enhanced enzymatic activity of IP -synthesizing kinases in the human ALS spinal cord. In contrast, human CSF did not contain detectable level of IP and IP , and neither the IP level nor the IP /IP ratio in human PBMCs differentiated ALS patients from age-matched healthy individuals. By directly analyzing IP in the CNS of ALS mice and humans, the findings of this study provide direct evidence that IP level and/or the enzymatic activity of IP -generating kinases IP6Ks are elevated in ALS spinal cord. On the other hand, this study also showed that IP is not suitable for biofluid-based ALS diagnosis. Further investigation is required to elucidate a role of IP in ALS pathology and utilize IP metabolism on the diagnostic application of ALS.</abstract><cop>Switzerland</cop><pmid>38274887</pmid></addata></record>
fulltext fulltext
identifier ISSN: 1664-2295
ispartof Frontiers in neurology, 2023, Vol.14, p.1334004
issn 1664-2295
1664-2295
language eng
recordid cdi_pubmed_primary_38274887
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central
title Elevation of inositol pyrophosphate IP 7 in the mammalian spinal cord of amyotrophic lateral sclerosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A12%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevation%20of%20inositol%20pyrophosphate%20IP%207%20in%20the%20mammalian%20spinal%20cord%20of%20amyotrophic%20lateral%20sclerosis&rft.jtitle=Frontiers%20in%20neurology&rft.au=Ito,%20Masatoshi&rft.date=2023&rft.volume=14&rft.spage=1334004&rft.pages=1334004-&rft.issn=1664-2295&rft.eissn=1664-2295&rft_id=info:doi/&rft_dat=%3Cpubmed%3E38274887%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/38274887&rfr_iscdi=true